ReviewMolecular psychiatry2017
An update on stem cell biology and engineering for brain development.
Review in Molecular psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A neurorecording toolkit for longitudinal assessments of transplanted human cortical organoidsbioRxiv : the preprint server for biology · 2025Article
- Modeling of the brain-lung axis using organoids in traumatic brain injury: an updated review.Cell & bioscience · 2024Review
- Characterization of neural mechanotransduction response in human traumatic brain injury organoid model.Scientific reports · 2023Article
- Advances in the knowledge and therapeutics of schizophrenia, major depression disorder, and bipolar disorder from human brain organoid research.Frontiers in psychiatry · 2023Review
- Advances in construction and modeling of functional neural circuits in vitro.Neurochemical research · 2022Article
- Long-term adherence of human brain cells in vitro is enhanced by charged amine-based plasma polymer coatings.Stem cell reports · 2022Article
- Accelerated neuronal agingFrontiers in aging neuroscience · 2022Review
- Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders.The international journal of neuropsychopharmacology · 2021Review
- Modeling Neurological Disorders in 3D Organoids Using Human-Derived Pluripotent Stem Cells.Frontiers in cell and developmental biology · 2021Review
- Spheroids as a Type of Three-Dimensional Cell Cultures-Examples of Methods of Preparation and the Most Important Application.International journal of molecular sciences · 2020Review
- Article
- Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.NPJ Parkinson's disease · 2020Review
- Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders.Molecular neurobiology · 2019Review
- 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development.Methods in molecular biology (Clifton, N.J.) · 2019Review
- Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- hiPSC-derived neural stem cells from patients with schizophrenia induce an impaired angiogenesis.Translational psychiatry · 2018Article
- Modeling psychiatric disorders using patient stem cell-derived neurons: a way forward.Genome medicine · 2018Article
- Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes.PloS one · 2018Article
- Three-Dimensional Organoid System Transplantation Technologies in Future Treatment of Central Nervous System Diseases.Stem cells international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two recent technologies, induced-pluripotent stem cells (iPSCs) and direct somatic reprogramming, have shown enormous potential for cell-based therapies against intractable diseases such as those that affect the central nervous system. Already, methods that generate most major cell types of the human brain exist. Whether the cell types are directly reprogrammed from human somatic cells or differentiated from an iPSC intermediate, the overview presented here demonstrates how these protocols vary greatly in their efficiencies, purity and maturation of the resulting cells. Possible solutions including micro-RNA switch technologies that purify target cell types are also outlined. Further, an update on the transition from 2D to 3D cultures and current organoid (mini-brain) cultures are reviewed to give the stem cell and developmental engineering communities an up-to-date account of the progress and future perspectives for modeling of central nervous system disease and brain development in vitro.
Indexed as
Identifiers
28373686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.